

Fernando Torres

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6982622/publications.pdf>

Version: 2024-02-01

49
papers

4,367
citations

361045

20
h-index

223531

46
g-index

49
all docs

49
docs citations

49
times ranked

5635
citing authors

#	ARTICLE	IF	CITATIONS
1	Definitions and Diagnosis of Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D42-D50.	1.2	1,467
2	Telomere Shortening in Familial and Sporadic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 729-737.	2.5	481
3	Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. <i>Nature Genetics</i> , 2015, 47, 512-517.	9.4	385
4	Diagnosis of pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801904.	3.1	333
5	Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C) Tj ETQq1 1 0784314.pdf / Over	0.7	4314
6	Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. <i>Lancet Respiratory Medicine</i> , 2014, 2, 557-565.	5.2	225
7	Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1102-1110.	2.5	138
8	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 227-238.	5.2	122
9	Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1366-1375.	0.3	103
10	Telomere length in patients with pulmonary fibrosis associated with chronic lung allograft dysfunction and post-lung transplantation survival. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 845-853.	0.3	93
11	Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 209-221.	2.5	88
12	International Classification of Diseases Coding Changes Lead to Profound Declines in Reported Idiopathic Pulmonary Arterial Hypertension Mortality and Hospitalizations. <i>Chest</i> , 2011, 139, 497-504.	0.4	61
13	Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines. <i>Vaccines</i> , 2021, 9, 708.	2.1	51
14	Hemodynamics and Epoprostenol Use Are Associated With Thrombocytopenia in Pulmonary Arterial Hypertension. <i>Chest</i> , 2009, 135, 130-136.	0.4	49
15	Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System. <i>Chest</i> , 2016, 150, 27-34.	0.4	48
16	Imatinib in Pulmonary Arterial Hypertension: Kit Inhibition. <i>Pulmonary Circulation</i> , 2014, 4, 452-455.	0.8	35
17	Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. <i>European Respiratory Journal</i> , 2019, 54, 1901030.	3.1	33
18	Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1059-1067.	1.6	30

#	ARTICLE	IF	CITATIONS
19	Characteristics and outcomes among patients with need for early dialysis after lung transplantation surgery. <i>Clinical Transplantation</i> , 2017, 31, e13106.	0.8	28
20	Treprostinil for the treatment of pulmonary arterial hypertension. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 13-25.	0.6	25
21	Long-term Therapy with Oral Treprostinil in Pulmonary Arterial Hypertension Failed to Lead to Improvement in Important Physiologic Measures: Results from a Single Center. <i>Pulmonary Circulation</i> , 2015, 5, 513-520.	0.8	21
22	Lung transplantation and gender effects on survival of recipients with cystic fibrosis. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1487-1496.	0.3	21
23	Predictors of outcome among patients on extracorporeal membrane oxygenation as a bridge to lung transplantation. <i>Clinical Transplantation</i> , 2017, 31, e12990.	0.8	20
24	Clinical characteristics, management practices, and outcomes among lung transplant patients with COVID-19. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 936-947.	0.3	19
25	Right atrial emptying fraction non-invasively predicts mortality in pulmonary hypertension. <i>International Journal of Cardiovascular Imaging</i> , 2016, 32, 1121-1130.	0.7	18
26	Mortality in Patients With Pulmonary Arterial Hypertension Treated With Continuous Prostanoids. <i>Chest</i> , 2018, 154, 532-540.	0.4	17
27	Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1). <i>Respiratory Medicine</i> , 2017, 126, 84-92.	1.3	15
28	Post-infection pulmonary sequelae after COVID-19 among patients with lung transplantation. <i>Transplant Infectious Disease</i> , 2021, 23, e13739.	0.7	14
29	Association of pretransplant kidney function with outcomes after lung transplantation. <i>Clinical Transplantation</i> , 2017, 31, e12932.	0.8	13
30	Long-term results of the DelIVery for Pulmonary Arterial Hypertension trial. <i>Pulmonary Circulation</i> , 2019, 9, 204589401987861.	0.8	12
31	Incidence and variables associated with 30-day mortality after lung transplantation. <i>Clinical Transplantation</i> , 2019, 33, e13468.	0.8	11
32	Severe pulmonary arterial hypertension: stratification of medical therapies, mechanical support, and lung transplantation. <i>Heart Failure Reviews</i> , 2016, 21, 347-356.	1.7	10
33	Significance of Best Spirometry in the First Year After Bilateral Lung Transplantation: Association With 3-Year Outcomes. <i>Transplantation</i> , 2020, 104, 1712-1719.	0.5	9
34	Characteristics and Outcomes of Lung Transplant Candidates With Preexisting Renal Dysfunction. <i>Transplantation Proceedings</i> , 2020, 52, 302-308.	0.3	9
35	Characteristics and outcomes among vaccinated lung transplant patients with breakthrough COVID-19. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	9
36	Interaction of pre-transplant recipient characteristics and renal function in lung transplant survival. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 275-282.	0.3	7

#	ARTICLE	IF	CITATIONS
37	Pre-existing self-reactive IgA antibodies associated with primary graft dysfunction after lung transplantation. <i>Transplant Immunology</i> , 2020, 59, 101271.	0.6	6
38	Evaluation of current strategies for surveillance and management of donor-specific antibodies: Single-center study. <i>Clinical Transplantation</i> , 2018, 32, e13285.	0.8	5
39	Prognostic Value of Echocardiographic Variables Prior to and Following Initiation of Parenteral Prostacyclin Therapy. <i>Chest</i> , 2022, 162, 669-683.	0.4	5
40	Characteristics and outcomes among patients with community-acquired respiratory virus infections during the first year after lung transplantation. <i>Clinical Transplantation</i> , 2021, 35, e14140.	0.8	3
41	Self-reactive antibodies associated with bronchiolitis obliterans syndrome subtype of chronic lung allograft dysfunction. <i>Human Immunology</i> , 2021, 82, 25-35.	1.2	3
42	Characteristics and outcomes among lung transplant patients with respiratory syncytial virus infection. <i>Transplant Infectious Disease</i> , 2021, 23, e13661.	0.7	3
43	Effects of Extracorporeal Membrane Oxygenation Initiation on Oxygenation and Pulmonary Opacities. <i>The Journal of Critical Care Medicine</i> , 2021, 7, 6-13.	0.3	2
44	Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction. <i>Journal of Thoracic Disease</i> , 2021, 13, 1466-1475.	0.6	2
45	Spectrum of findings on ventilation-perfusion lung scintigraphy after lung transplantation and association with outcomes. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 377-386.	0.3	2
46	Insult to Injury: Development of Alveolar Hemorrhage after Initiation of Extracorporeal Membrane Oxygenation. <i>Indian Journal of Critical Care Medicine</i> , 2020, 24, 1201-1205.	0.3	1
47	Diaphragmatic plication among lung transplant patients: A single-center experience. <i>Clinical Transplantation</i> , 2022, , e14683.	0.8	1
48	FP804TWO-YEAR DURABILITY OF IMPROVEMENTS IN EGFR WITH BARDOXOLONE METHYL IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: THE LARIAT STUDY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i634-i634.	0.4	0
49	P0229APPLICATION OF A RISK MITIGATION STRATEGY TO PREVENT EXCESS CARDIOVASCULAR RISK IN PULMONARY HYPERTENSION: LARIAT STUDY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0